tiprankstipranks
Sareum Holdings Reports Promising Phase 1 Results
Company Announcements

Sareum Holdings Reports Promising Phase 1 Results

Sareum Holdings (GB:SAR) has released an update.

Don't Miss our Black Friday Offers:

Sareum Holdings has announced encouraging results from its Phase 1 clinical trial for SDC-1801, a new treatment for autoimmune diseases, showing achievement of therapeutic blood plasma levels without serious side effects. The successful trial suggests the possibility of once-daily dosing due to the drug’s long half-life and sets the stage for advancing to the next phase of development. Further detailed data on the trial is anticipated to be released in the third quarter of 2024.

For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskSareum Holdings Advances in Autoimmune and Cancer Drug Development
TipRanks UK Auto-Generated NewsdeskSareum Holdings Secures Additional Funding for Drug Development
TipRanks UK Auto-Generated NewsdeskSareum Holdings Secures Funds for Phase 2 Trials
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App